Abstract:Objective: Describe the characteristics and prevalence of headache in patients with mitochondrial diseases (MDs), as well as sleep quality, trying to observe possible associations. To assess whether these patients are more likely to suffer headaches in relation to poorer quality of sleep. Background: Sleep disorders and headache are considered to be common in MDs. We present the largest sample analyzed to date. Methods: Observational, descriptive, cross-sectional study that analyzed a database of 232 patients with MDs, including age, sex, genotype, phenotype, presence and characteristics of headache. All patients fulfilled the Epworth Sleepiness Scale (ESS), the Pittsburgh Sleep Quality Index (PSQI) and, in migraine, the Migraine Disability Assessment questionnaire (MIDAS). Headache was divided into two groups: migraine headache, according to criteria of the International Classification of Headache Disorders (ICHD-III beta), and non-migraine headache. Results: A total of 203 cases were analyzed, 124 women (61%) and 79 men (39%). Average age was 46 years. Most frequent DNA mutation was m.3243 A > G in MITL1 gene (33%). Most frequent phenotype was MELAS syndrome: 28 patients (13.8%). Ninety-two patients (45.3%), reported headache, 44 fulfilling migraine criteria (21.7%). Headache was more frequent in MELAS syndrome ( p < 0.01). Statistically significant differences were found in the number of disabling episodes per month in patients with migraine ( p < 0.001). Patients with headache scored higher in Epworth ( p = 0.01) and Pittsburgh scales ( p < 0.001). Conclusions: A higher prevalence of migraine is observed in patients with mitochondrial diseases, independent of genotype and phenotype. MD-associated migraine tends to be chronic and more disabling. A higher frequency of headache, not specifically migraine, has also been observed in patients with MELAS syndrome. Mitochondrial dysfunction could be one of the pathophysiological mechanisms of migraine and a factor of chronification and severity. Poor sleep quality could also be associated with headache in patients with MDs. Assessment of headache and sleep disturbances should be part of the routine workup of patients with mitochondrial disease. Trial registration: N/A.

Migräne und mitochondriale Erkrankungen

Energy metabolism disturbance in migraine: From a mitochondrial point of view

Therapeutic and tampering approaches for mitochondrial associated diseases

Es tut sich viel in der Migräne- und Kopfschmerz-Therapie!

The metabolic face of migraine — from pathophysiology to treatment

Epilepsy in Mitochondrial Diseases—Current State of Knowledge on Aetiology and Treatment

Mutations of the mitochondrial genome: clinical overview and possible pathophysiology of cell damage

The Role of MicroRNAs in Mitochondria-Mediated Eye Diseases

Headache and sleep quality in mitochondrial diseases

Insights into Major Depression as a Mitochondria-Associated Disease

Mitochondrial diseases in adults

Mitochondria and vision – a life in mitochondria always on the move

Mitochondrial diseases caused by toxic compound accumulation: from etiopathology to therapeutic approaches

A Clinical-Pathophysiological Perspective

Mitochondrial dysfunction and cerebral metabolic abnormalities in patients with mitochondrial encephalomyopathy subtypes: Evidence from proton MR spectroscopy and muscle biopsy

[Myalgic encephalomyelitis : etiopathogenesis, diagnosis and treatment]

Neues aus der Akuttherapie der Migräne

Neuroimaging in mitochondrial disease

Mitochondria and the eye—manifestations of mitochondrial diseases and their management

Perceived association of mood and symptom severity in adults with mitochondrial diseases

Migraine-associated risks and comorbidity